Physician profile
Virendra Ranadive
NPI 1447211149
$40,772.57
in general payments reported to CMS, 2019-2025
68 companies · $3,263 in 2025
The $3,263 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,870 · 2021: $7,444 · 2022: $4,889 · 2023: $4,327 · 2024: $3,054 · 2025: $3,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,462 · Consulting Fee: $1,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,461.66 |
| Consulting Fee | $1,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $182.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17,956.58 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $2,612.96 | 2020-2025 | |
| Argenx US, INC. | $2,028.48 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $1,818.63 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Abbvie INC. | $1,494.46 | 2019-2025 | |
| Mdd US Operations, LLC | $1,271.22 | 2019-2024 | Apokyn, Gocovri, Gocovri |
| Acadia Pharmaceuticals INC | $958.40 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $880.67 | 2020-2025 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $798.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $713.85 | 2019-2025 | |
| Kyowa Kirin, INC. | $626.01 | 2019-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $560.11 | 2019-2025 | Crexont, Lyvispah, Rytary |
| Pfizer INC. | $530.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.71 | 2021-2025 | Wainua |
| Lilly USA, LLC | $472.37 | 2019-2024 | Amyvid, Emgality |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virendra Ranadive listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.